Alani Asis is a freelancer for Newsweek’s personal finance vertical. Alani has over three years of experience writing for personal finance brands such as Insider, Forbes and Fortune Magazine.

Japanese drugmaker Eisai Co. Ltd. said on Monday it had submitted a marketing authorization application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

Edward J. “Mac” McDonough, a former Baltimore Sun editor who later became a public information officer for the state Department of Emergency Management, died Jan. 12 of a massive heart attack ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate ...

Lecanemab, from Biogen and Japanese partner Eisai Co., is sold under the brand name Leqembi, and donanemab from Eli Lilly is branded as Kisunla. Both drugs work by reducing the brain amyloid ...

According to the Court Circular, Prince Edward, 60, arrived at Lennart Meri Tallinn Airport on Thursday afternoon, where he was greeted by the ambassador to the Republic of Estonia, His Excellency ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

President John Dramani Mahama has appointed Edward Abambire Bawa as the Acting Chief Executive Officer of the Ghana National Petroleum Corporation (GNPC). His appointment takes effect from January ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...